Purpose: The objective of this study was to evaluate the palliative treatment benefit of surface-mold computer-optimized high-dose-rate brachytherapy (SMBT) for in-transit cutaneous metastases of Merkel cell carcinoma (MCC).
M erkel cell carcinoma (MCC) is a rare (È1500 cases per year) and aggressive (È33% mortality) cutaneous neuroendocrine carcinoma that favors ultraviolet-exposed skin of the head and neck as well as the extremities in older white patients. 1, 2 The incidence of MCC is increased in immunosuppressed patients with organ transplantation, chronic lymphocytic leukemia, and human immunodeficiency virus. 1, 3 Although the molecular pathogenesis remains largely unknown, a novel Merkel cell polyomavirus was identified in 100% of tumors. 4, 5 Merkel cell carcinoma exhibits a propensity for early regional involvement and distant relapse. 6 Survival is dependent on disease stage at diagnosis with the 5-year disease-specific survival at 97% for skinlimited disease, 52% for regional lymph node disease, and 11% for distant metastatic disease. 7 Although treatment is dependent on stage, radiation therapy is favored as MCC is a highly radiosensitive tumor. 8 Despite aggressive management with wide local excision (WLE) and radiation therapy (RT), 9Y12 locoregional recurrence and metastatic progression are nonetheless common. 6 In-transit metastases are common on the lower extremities and are more rarely seen on the head and neck. Untreated, in-transit cutaneous metastases often amalgamate into large malodorous ulcerated tumors that can cover an entire limb ( Fig. 1 ). As such, they can become cosmetically disfiguring, pose a wound care challenge for patients and their caregivers, and present impairments to the patient's quality of life. Treatment may be challenging as in-transit metastases are often multifocal; tend to be located on the curved surfaces of the extremities, making conventional external-beam RT technically challenging; and may appear adjacent to previously treated fields with poor tolerance for additional therapy (Fig. 2 ). In-transit lesions are often too numerous for clear margin excision, and resection carries risks of poor wound healing in the setting of preexisting or evolving lymphedema. Response to chemotherapy is variable and rarely durable. 13 Isolated limb perfusion/infusion may be complicated by tissue necrosis, muscle injury, compartment syndrome, vascular thrombosis, paresthesias, and nerve palsies as well as systemic toxicities. 14, 15 Palliative surface-mold computer-optimized highdose-rate (HDR) brachytherapy (SMBT) overcomes these limitations and offers a well-tolerated treatment with effective and durable local control.
Previously, we published the first case report describing the use of SMBT for palliation of in-transit cutaneous metastases of MCC on the lower extremity. 16 Here, we describe treatment outcomes and disease course in 9 additional patients treated with SMBT.
METHODS

Patients
We obtained approval from the institutional review board at Dana-Farber/Brigham & Women's Cancer Center (DF/ BWCC) for our study. From our MCC patient database, we identified and included all patients (n = 10) with in-transit cutaneous metastases treated with SMBT at the DF/BWCC between January 2006 and November 2012. All patients were diagnosed with MCC that was confirmed by histology. Patient demographics and treatment response were extracted from electronic medical records.
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SMBT Treatment Protocol
As described in our previous publication, radiopaque markers were placed over in-transit cutaneous metastases, and computed tomography guide wires outlined the treatment margin that, in most cases, extended 2 cm around all metastases ( Fig. 3A) . A moldable 5 Â 5 cm Freiburg flap applicator (Elekta, Inc, Norcross, Ga), composed of hollow HDR treatment catheters spaced at 1-cm intervals ( Fig. 4 ), was custom sized to cover a treatment field. Lesions within the 2-cm treatment margin of another lesion as well as normal skin spanning a few centimeters between 2 treatment areas were often encompassed by 1 applicator in the same field (Figs. 3A, B). A single 1 Â 3-mm radioactive seed of the gamma emitter iridium 192 was then directed to separate positions (eg, ''dwell'' positions) within the hollow catheters. The location of the dwell positions and the amount of time the radioactive source rested at each position were computer optimized to provide the most uniform radiation dose to the targeted lesions ( Fig. 3C ). Typically, a total prescribed dose of 12 Gy was delivered in 2 equal fractions, 1 or 2 days apart, to a target depth of 5 to 10 mm based on clinical and radiographic findings.
RESULTS
The median age at diagnosis was 76 years (range, 63Y87 years). All patients (100%) were white. There were 6 men (60%) and 4 women (40%). At diagnosis, 2 patients were at stage IB (20%), 2 were at stage IIA (20%), 3 were at stage IIIA (30%), and 3 were at stage IIIB (30%). Seven patients had in-transit metastases on the lower extremities (70%), 2 patients on the head and neck (20%), and 1 patient on an upper extremity (10%). Initial treatment consisted of WLE alone in 3 patients (30%); WLE and locoregional RT in 2 patients (20%); WLE, locoregional RT, and chemotherapy in 3 patients (30%); and regional RT and chemotherapy in a single patient (10%). The initial site of relapse for all 10 patients (100%) was in-transit on previously untreated skin at a median time of 9 months after diagnosis (range, 1Y45 months). Two patients received salvage chemotherapy for in-transit cutaneous metastases before referral to the DF/BWCC (Table 1) . Surface-mold computeroptimized high-dose-rate brachytherapy was selected over conventional therapy as in-transit cutaneous metastases tended to be in close proximity to surgical sites (9/10 [90%]) or previously irradiated fields (7/10 [70%]) and unresponsive to previous chemotherapy given as part of the initial management (4/10 [40%]) or salvage treatment (2/10 [20%]).
A total of 152 metastatic MCC lesions were treated with SMBT, with each patient receiving treatment for anywhere from 2 to 36 lesions with anywhere from 1 to 10 fields, sometimes over multiple sessions. Most patients received 1200 cGy in 2 equal fractions to a target depth of 5 to 10 mm based on their physical examination as well as findings on imaging studies. Two patients (20%) received 1000 cGy in 2 equal fractions, because of significant lymphedema at presentation. The median follow-up was 34 months (range, 22Y85 months) ( Table 1 ). All in-transit cutaneous metastases treated with SMBT resolved within a few weeks of treatment. Treatment response was durable as 149 of 152 of lesions did not recur during the study period (99% control rate). Two patients (20%) experienced recurrence of a single lesion in the previous SMBT field, 1 at 25 months after SMBT in the setting of diffuse metastatic disease and the other at 2 months after SMBT in a lesion that was underdosed by 33%. Treatment adverse effects included mild erythema in all patients (100%) and ulceration in 2 patients (20%), both of whom were treated in the setting of significant lymphedema.
Two patients (20%) who underwent more than 1 course of SMBT treatment are alive without evidence of local or distant disease (AWOD). Eight patients (80%) developed additional intransit cutaneous metastases outside their original SMBT field on the affected extremity (median, 2 episodes; range 1Y5 episodes). Five of these 8 patients had further SMBT resulting in resolution of these additional in-transit cutaneous metastases. Three of these 5 patients who underwent additional SMBT treatments are AWOD. All of the patients (100%) had outside SMBT field recurrence, with 80% having in-transit metastases, 70% having regional metastases, and 70% having distant metastases. Overall, 3 patients (30%) are AWOD, 3 (30%) are alive with disease, and 4 (40%) died of MCC (Table 1) . In-transit (7, 15), regional ( 
DISCUSSION
In keeping with the literature, our study population was white (100%) and older (median age of 76 years) with a slight male-to-female preponderance (1.5:1). 1, 2 In-transit cutaneous metastases were most commonly seen on the extremities (80%), where lymphatic drainage is more predictable. This is not surprising as locoregional control rates for lower-extremity MCCs have been reported to be as low as 15%. 13, 17 Interestingly, 2 patients with a history of polio developed in-transit cutaneous metastases in the affected limb. One of these patients also had elephantiasis nostras verrucosa complicated by severe lymphedema (Fig. 5 ). We also observed in-transit cutaneous metastases on the head and neck (20%), which were less common. The risk for the development of in-transit cutaneous metastases appeared to be associated more with the anatomic location of the primary tumor (eg, lower extremities) than with the stage of disease at presentation. Indeed, in-transit cutaneous metastases were observed in both local disease for primary tumors less than or equal to 2 cm (stage IB) and greater than 2 cm (stage IIA), as well as regional lymph node disease (stage IIIA and B). In our patients, in-transit cutaneous metastases tended to be multifocal (median of 10 lesions [range, 2Y36 lesions]), located between the primary site and regional lymph nodes as well as retrograde to the primary tumor bed. Indeed, 1 patient presented to the DF/BWCC with a recommendation for limb amputation due to the multifocality of in-transit cutaneous metastases (Fig. 5 ). In-transit metastases presented as both violaceous nodules on the surface of the skin (Fig. 5 ) as well as palpable subcutaneous nodules with no overlying skin changes (Fig. 2) .
We treated a total of 152 lesions with SMBT. All lesions resolved clinically within a few weeks of treatment (Fig. 3D) . During a median follow-up of 34 months (range, 22Y85 months), there were only 2 in-SMBT-field recurrences. As described in our previous publication, 1 in-SMBT-field recurrence was histologically documented at 25 months after SMBT in the setting of diffuse metastatic disease to which the patient ultimately succumbed. The other was noted clinically at 2 months after SMBT in a patient who received 33% less than the prescribed dose. Local control rates were thus superb at 99% (149/152). There was high patient acceptability as duration of treatment typically spanned 2 treatments, each lasting under 1 hour, 2 days apart in contrast to conventional external-beam RT, which may span 3 or more weeks. Patient tolerance was good with only mild to moderate erythema (100%) in the treatment field. Two patients (20%) with severe lymphedema, however, developed ulceration in the SMBT field, despite dose reduction. As the prescribed dose was delivered to a target depth of 5 to 10 mm with a sharp dose fall-off at the edge of the treatment field, no patients experienced posttreatment fibrosis, worsening lymphedema, or damage to surrounding skin, muscle, or bone.
The prognosis for patients who develop in-transit cutaneous metastases is poor with a relative survival of less than 30% at 5 years. 18 Our study cohort fared no better as only 3 patients (30%) who received serial SMBT for additional in-transit metastases are alive without disease. In-transit cutaneous metastases portend a grave prognosis and often herald distant progression with a fatal outcome. Indeed, the remaining 7 patients in our study (70%) have developed distant metastatic disease, with 4 succumbing to MCC (40%).
We conclude that SMBT offers both effective and durable palliation for MCC patients with in-transit cutaneous metastases but does not alter disease course. Although our study is limited by small numbers, and further studies are warranted, SMBT should nonetheless be given due consideration in the palliation of in-transit cutaneous metastases where treatment options are limited.
